|
| Tuesday, November 30, 2021 |
|
|
Eisai and FCNT Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia |
| Eisai Co., Ltd. and FCNT LIMITED announced today that both companies have entered into a business alliance agreement aiming to support people living with dementia and to prevent dementia, through developing solutions for maintaining brain performance. more info >> |
|
|
Eisai to Present Latest Data on Perampanel and E2730 at the 75th American Epilepsy Society Annual Meeting |
| Eisai Co., Ltd. announced today that the company will conduct a total of 42 poster presentations, including the latest data on its in-house discovered and developed anti-epileptic agent (AED) perampanel (product name: Fycompa) and in-house discovered and developed E2730 at the 75th American Epilepsy Society Annual Meeting (AES2021), to be held in Chicago, Illinois and virtually from December 3 to 7, 2021. more info >> |
|
| Monday, November 29, 2021 |
|
|
エーザイとMSD、「レンビマ(R)」と「キイトルーダ(R)」の併用療法による子宮内膜がんに係る承認を欧州委員会より取得 |
| エーザイとMSD、「レンビマ(R)」と「キイトルーダ(R)」の併用療法による子宮内膜がんに係る承認を欧州委員会より取得 more info >> |
|
|
European Commission Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) for Patients With Certain Types of Endometrial Carcinoma |
| Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced that the European Commission has approved the combination of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA. more info >> |
|
|
European Commission Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma |
| Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced that the European Commission has approved the combination of LENVIMA (KISPLYX in the European Union [EU] for the treatment of advanced renal cell carcinoma [RCC]). more info >> |
|
| Friday, November 19, 2021 |
|
|
エーザイ、社会的責任投資指数「Dow Jones Sustainability Asia Pacific Index」に8回目の選定 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、社会的責任投資（Social Responsibility Investment: SRI）の世界的投資指数である「Dow Jones Sustainability Index」（DJSI)のアジア・太平洋版「DJSI Asia Pacific Index」の対象銘柄に選定されましたのでお知らせします。当社は今回が 8 回目の選定となります。 more info >> |
|
|
エーザイ、IR優良企業賞2021において「“共感！”IR賞」を受賞 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫、以下 エーザイ）は、このたび、 一般社団法人日本IR協議会（会長：泉谷直木）が選定するIR優良企業賞2021において、「“共感！”IR賞」を受賞しましたのでお知らせします。 more info >> |
|
| Thursday, November 18, 2021 |
|
|
Eisai Receives the 'Most Liked!' IR Award at The 2021 IR Award |
| Eisai Co., Ltd. has announced that it has been selected as the winner of the "Most Liked!" IR Award at the 2021 IR Award, hosted by the Japan Investor Relations Association. more info >> |
|
|
バイオジェンとエーザイ、ＥＵにおけるアデュカヌマブの承認審査状況について |
| バイオジェン・インク（Nasdaq: BIIB、本社：米国マサチューセッツ州ケンブリッジ、CEO：ミシェル・ヴォナッソス、以下 バイオジェン）とエーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫、以下 エーザイ）は、このたび、欧州医薬品庁（EMA）の欧州医薬品委員会（Committee for Medicinal Products for Human Use: CHMP）によるアルツハイマー病（AD）治療薬としてのアデュカヌマブ注射100 mg / mL溶液の販売承認申請（MAA）の審査状況について最新情報をお知らせします。 more info >> |
|
| Friday, November 12, 2021 |
|
|
Eisai: New Phase 3 Data Show Positive Correlation Between ADUHELM Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer's Disease |
| Biogen Inc. and Eisai Co., Ltd. (Tokyo, Japan) announced that data from approximately 7,000 plasma samples from more than 1,800 patients in the ADUHELM (aducanumab-avwa) Phase 3 clinical trials showed a statistically significant correlation between plasma p-tau reduction and less cognitive and functional decline in Alzheimer's disease. more info >> |
|
|
|
|
